NNIT A/S (CPH:NNIT)
Denmark · Delayed Price · Currency is DKK | Market Cap | 1.02B -39.7% |
| Revenue (ttm) | 1.79B -3.4% |
| Net Income | -24.00M |
| EPS | -0.97 |
| Shares Out | 24.90M |
| PE Ratio | n/a |
| Forward PE | 10.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,239 |
| Average Volume | 12,443 |
| Open | 40.70 |
| Previous Close | 40.90 |
| Day's Range | 40.45 - 41.40 |
| 52-Week Range | 38.85 - 76.40 |
| Beta | 0.47 |
| RSI | 39.87 |
| Earnings Date | Aug 27, 2026 |
About NNIT A/S
NNIT A/S provides information technology solutions for life sciences, public, and private sectors in Denmark, Europe, the United States, and Asia. The company provides cybersecurity, regulatory affairs, AI, laboratory, drug safety, compliance, quality, SAP solutions, software engineering, digital manufacturing, clinical, data and cloud, supply chain, tech transition consulting, legacy transformation, and first-time launch services, as well as Microsoft and Veeva solutions, and migration solutions by valiance. NNIT A/S was founded in 1994 and is... [Read more]
Financial Performance
Financial StatementsNews
Q1 2026 NNIT A/S Earnings Call Transcript
Q1 2026 NNIT A/S Earnings Call Transcript
NNIT A/S Earnings Call Transcript: Q1 2026
Q1 2026 saw a 9% revenue decline and weak profitability, prompting revised negative growth guidance and intensified cost and sales initiatives. New AI platforms were launched, and segment performance varied, with Life Sciences declining and SCALES growing strongly.
NNIT A/S Earnings Call Transcript: Q4 2025
Q4 2025 saw revenue and margin declines due to market unrest in Europe and U.S. project delays, but full-year results met revised expectations. Strategic focus on life science and public segments, cost reductions, and improved free cash flow position the company for 2026 growth.
NNIT A/S Earnings Call Transcript: Q3 2025
Q3 saw profitability more than double year-over-year, driven by cost optimization and strategic execution, despite a slight revenue decline. New contract wins and improved margins across most regions support a maintained full-year outlook at the lower end of guidance.
Q2 2025 NNIT A/S Earnings Call Transcript
Q2 2025 NNIT A/S Earnings Call Transcript
NNIT A/S Earnings Call Transcript: Q2 2025
Q2 2025 revenue declined 2.5% year-over-year, mainly due to weakness in Europe, but the U.S. and Asia showed growth. Cost-saving initiatives and a sharpened solution focus are expected to support margin improvement, with full-year guidance maintained at the low end of the range.
NNIT A/S Earnings Call Transcript: Q1 2025
Q1 2025 saw flat revenue and negative organic growth amid market uncertainty, with regional disparities: growth in Asia and Denmark offset by declines in Europe and the U.S. Full-year guidance was lowered, and cost-saving measures, including workforce reductions, were implemented.
NNIT A/S Earnings Call Transcript: Q4 2024
2024 ended with 6% organic growth and improved Q4 profitability, despite market headwinds and restructuring. 2025 guidance targets 7%-10% organic growth and higher margins, with special items and restructuring costs set to decline. Novo Nordisk was a key growth driver.
NNIT A/S Earnings Call Transcript: Q3 2024
Q3 2024 saw revenue and profit margins decline due to slow recovery in data migration and a life sciences market slowdown. Major contract wins and capacity adjustments are expected to drive a return to profitable growth in Q4, with full-year guidance revised downward.
NNIT A/S Earnings Call Transcript: Q2 2024
Q2 saw 11.8% revenue growth and margin improvement, driven by strong performance in Europe, Denmark, and a turnaround in Asia, while the U.S. faced data migration headwinds. Full-year guidance is reaffirmed, with profitability expected to accelerate in H2.